Litigation Details for AMGEN INC. v. KASHIV BIOSCIENCES, LLC (D.N.J. 2018)
✉ Email this page to a colleague
AMGEN INC. v. KASHIV BIOSCIENCES, LLC (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-03-07 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-11-24 |
| Cause | 15:1126 Patent Infringement | Assigned To | Claire Claudia Cecchi |
| Jury Demand | None | Referred To | Mark Falk |
| Parties | AMNEAL PHARMACEUTICALS, LLC | ||
| Patents | 7,384,765 | ||
| Attorneys | ERIC ALAN STONE | ||
| Firms | Rivkin Radler LLP | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in AMGEN INC. v. KASHIV BIOSCIENCES, LLC
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for AMGEN INC. v. KASHIV BIOSCIENCES, LLC (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-03-07 | 1 | The asserted patents are U.S. Patent Nos. 6,180,391, 7,083,948, 7,118,884, 7,384,765, 7,427,659, 7,…rights, title, and interest in U.S. Patent No. 7,384,765 (“the ’765 Patent”). 49. AML holds an…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent. For an…. This is an action for patent infringement arising under the patent laws of the United States, …Asserted Patents”). Amgen is the owner of all rights, title, and interest in the Asserted Patents. AML has | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
